Text Size

Cutamesine (SA4503) Protects Retinal Ganglion Cells in an Ocular Hypertension Model of Glaucoma Determined Using Detection of Apoptosing Retinal Cells Technology and RBPMS Cell Marker

Sharif N.A., Takashi O., Taniguchi T., Sasaoka M., Guo L., Choi S., Luong V., Cordeiro M.F.


  • 2025
  • J Ocul Pharmacol Ther
View publication
  • Therapeutic Area

    Back of the eye (BOTE)

  • Categories

    Preclinical development

  • Affiliations

    Ophthalmology Innovation Center, Santen Inc., Emeryville, California, USA; Institute of Ophthalmology, University College London (UCL), London, United Kingdom; Imperial College of Science and Technology, St. Mary's Campus, London, United Kingdom; Eye-ACP Duke-National University of Singapore Medical School, Singapore, Singapore; Singapore Eye Research Institute (SERI), Singapore, Singapore; Department of Pharmacy Sciences, Creighton University, Omaha, Nebraska, USA; Department of Pharmacology and Neuroscience, University of North Texas Health Sciences Center, Fort Worth, Texas, USA; Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, Texas Southern University, Houston, Texas, USA; Global Research and Development, Nanoscope Therapeutics Inc., Dallas, Texas, USA; Ophthalmology Innovation Center, Santen Pharmaceutical Co., Ltd., Nara, Japan; Novai Ltd., Reading, United Kingdom

Related Publications

Efficacy and Safety of Low-Concentration Atropine in Slowing Myopia Progression in Children in Japan: The Randomized, Double-Blind Phase II/III ORANGE Study

Ohno-Matsui K., Igarashi-Yokoi T., Migita Y., Yamakawa Y, on behalf of the ORANGE study investigators


Awareness of Myopia Associated Complications and Perspectives on Myopia Management Among Parents of Children with Myopia in France and the UK

Hafizi R., Deferne N., Paudel N., Angerer A., Hsieh H.-T.


Efficacy and Safety of Low-Concentration Atropine in Slowing Myopia Progression in Children in Japan: The Randomized, Double-Blind Phase 2/3 ORANGE Study

Ohno-Matsui K., Igarashi-Yokoi T., Migita Y., Yamakawa Y. on behalf of the ORANGE study investigators


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022